|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12345678910111213...5253» |
- | CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Trial suspension, IO biomarker, Gene therapy: WT1 TCR Gene Therapy for Leukaemia: A Phase I/II Safety and Toxicity Study (clinicaltrials.gov) - Jul 21, 2017
P1/2, N=18, Suspended, Sponsor: Cell Therapy Catapult
Recruiting --> Suspended
- | CMD-602 / Cell and Gene Therapy Catapult, Athenex, Baylor College of Medicine
Trial suspension: A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients (clinicaltrials.gov) - Jul 21, 2017
P1/2, N=25, Suspended, Sponsor: Cell Therapy Catapult
Recruiting --> Suspended Recruiting --> Suspended
- | Trial completion, Enrollment change: Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer (clinicaltrials.gov) - Jul 19, 2017
P1, N=29, Completed, Sponsor: California Cancer Consortium
Recruiting --> Suspended Active, not recruiting --> Completed | N=40 --> 29
- | riluzole / Generic mfg.
Trial primary completion date: Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) (clinicaltrials.gov) - Jul 17, 2017
P3, N=270, Active, not recruiting, Sponsor: AOSpine North America Research Network
Active, not recruiting --> Completed | N=40 --> 29 Trial primary completion date: Jun 2017 --> Jan 2018
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date: Preservation of Ovarian Function After Hematopoietic Cell Transplant (clinicaltrials.gov) - Jul 17, 2017
P2, N=19, Terminated, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Jun 2017 --> Jan 2018 N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015
- | cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date: Cyclophosphamide Plus T-Cell Transplantation for Patients With Hematologic Malignancies (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=9, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
N=47 --> 19 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2014 --> Apr 2015 Terminated --> Active, not recruiting | Trial primary completion date: May 2011 --> May 2020
- | cyclophosphamide / Generic mfg.
Enrollment closed, Trial primary completion date, Post-transplantation: Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide (clinicaltrials.gov) - Jul 13, 2017
P1/2, N=127, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Terminated --> Active, not recruiting | Trial primary completion date: May 2011 --> May 2020 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jun 2019
- |||| ulixertinib (BVD-523) / BioMed Valley Discoveries
Trial completion: Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Jul 13, 2017
P1/2, N=53, Completed, Sponsor: BioMed Valley Discoveries, Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2018 --> Jun 2019 Recruiting --> Completed
- | IRX5183 / Io Therap
Enrollment open: Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Jul 13, 2017
P1/2, N=40, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Completed Not yet recruiting --> Recruiting
- azacitidine / Generic mfg.
Trial primary completion date, Combination therapy: A Study of LDE255 in Combination With Azacitidine for High Risk Myelodysplastic Syndrome Patients (clinicaltrials.gov) - Jul 12, 2017
P1, N=36, Recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Dec 2017
- || guadecitabine (SGI-110) / Otsuka
Trial primary completion date: A Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a Response (clinicaltrials.gov) - Jul 12, 2017
P2, N=56, Active, not recruiting, Sponsor: Groupe Francophone des Myelodysplasies
Trial primary completion date: Sep 2016 --> Dec 2017 Trial primary completion date: Jul 2015 --> Feb 2016
- | fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg.
Trial withdrawal, Trial primary completion date: Unrelated HSCT in Patients With Fanconi Anemia (clinicaltrials.gov) - Jul 11, 2017
P=N/A, N=0, Withdrawn, Sponsor: Neena Kapoor, M.D.
Trial primary completion date: Jul 2015 --> Feb 2016 Enrolling by invitation --> Withdrawn | Trial primary completion date: Mar 2017 --> Mar 2016
- | RG7112 / Roche
Trial completion, Trial primary completion date: An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies (clinicaltrials.gov) - Jul 7, 2017
P1, N=11, Completed, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Withdrawn | Trial primary completion date: Mar 2017 --> Mar 2016 Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jun 2017
- | Soliris (eculizumab) / AstraZeneca
Trial completion: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria (clinicaltrials.gov) - Jun 30, 2017
P3, N=87, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jun 2017 No longer recruiting --> Completed
- | imatinib / Generic mfg.
Trial completion: Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia (clinicaltrials.gov) - Jun 30, 2017
P2, N=7, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, Gene therapy: Gene Therapy for the Treatment of Fanconi's Anemia Type C (clinicaltrials.gov) - Jun 30, 2017
P1, N=9, Completed, Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, plerixafor / Generic mfg.
Enrollment change: Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=1, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed N=20 --> 1
- || dasatinib / Generic mfg.
Trial primary completion date: Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry Study (clinicaltrials.gov) - Jun 28, 2017
P=N/A, N=300, Active, not recruiting, Sponsor: Bristol-Myers Squibb
N=20 --> 1 Trial primary completion date: Apr 2017 --> Jul 2017
- Synribo (omacetaxine mepesuccinate) / Teva
Trial termination, Trial primary completion date: Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) (clinicaltrials.gov) - Jun 26, 2017
P2, N=2, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Apr 2017 --> Jul 2017 Active, not recruiting --> Terminated | Trial primary completion date: May 2018 --> Jun 2017; Slow Accrual-2 patients were registered Phase I and none in Phase II
- dasatinib / Generic mfg.
Trial termination: Dasatinib in Polycythemia Vera (clinicaltrials.gov) - Jun 20, 2017
P2, N=10, Terminated, Sponsor: Weill Medical College of Cornell University
Active, not recruiting --> Terminated | Trial primary completion date: May 2018 --> Jun 2017; Slow Accrual-2 patients were registered Phase I and none in Phase II Completed --> Terminated; This study was terminated due to lack of efficacy.
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Phase classification: Azacitidine, Darbepoetin Alfa, and Erythropoietin and Filgastrim (G-CSF) in Treating Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 20, 2017
P2, N=3, Terminated, Sponsor: Wake Forest University Health Sciences
Completed --> Terminated; This study was terminated due to lack of efficacy. Phase classification: P=N/A --> P2
- | deferasirox tablet for oral suspension / Generic mfg.
Phase classification: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jun 20, 2017
P2, N=16, Completed, Sponsor: Wake Forest University Health Sciences
Phase classification: P=N/A --> P2 Phase classification: P=N/A --> P2
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Trial primary completion date: Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 19, 2017
P=N/A, N=90, Active, not recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Phase classification: P=N/A --> P2 Trial primary completion date: Jun 2017 --> Jan 2017
- | Trial completion: HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies (clinicaltrials.gov) - Jun 19, 2017
P2, N=40, Completed, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Jun 2017 --> Jan 2017 Active, not recruiting --> Completed
- | Trial primary completion date: iCare3: Monitoring Circulating Cancer DNA After Chemotherapy in MDS and AML (clinicaltrials.gov) - Jun 19, 2017
P=N/A, N=20, Not yet recruiting, Sponsor: University of Florida
Active, not recruiting --> Completed Trial primary completion date: Dec 2018 --> Jan 2018
- | Trial completion, Trial primary completion date: APCORD: Cord Blood Transplantation in Severe Aplastic Anemia (clinicaltrials.gov) - Jun 15, 2017
P2, N=26, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Dec 2018 --> Jan 2018 Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jun 2017
- | indisulam (E7070) / Eisai
Trial completion, Trial primary completion date: E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 15, 2017
P2, N=43, Completed, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Jun 2017 Active, not recruiting --> Completed | Trial primary completion date: Feb 2019 --> Jun 2017
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Enrollment change, Metastases: Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=100, Completed, Sponsor: University of Illinois at Chicago
Active, not recruiting --> Completed | Trial primary completion date: Feb 2019 --> Jun 2017 N=152 --> 100
- | Vyxeos (cytarabine/daunorubicin liposomal formulation) / Jazz, Nippon Shinyaku
Enrollment open, Trial primary completion date: CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 14, 2017
P2, N=33, Recruiting, Sponsor: Bruno C. Medeiros
N=152 --> 100 Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019
- | Enrollment open: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 14, 2017
P1, N=30, Recruiting, Sponsor: Stanford University
Active, not recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Jul 2019 Active, not recruiting --> Recruiting
- || RG6146 / Roche
Enrollment change, Trial primary completion date: A Study of RO6870810/TEN-010 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 14, 2017
P1, N=51, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting N=37 --> 51 | Trial primary completion date: Aug 2017 --> Jan 2018
- Farydak (panobinostat) / Secura Bio
Trial primary completion date, Combination therapy, Epigenetic controller, Metastases: Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome (clinicaltrials.gov) - Jun 12, 2017
P1, N=28, Active, not recruiting, Sponsor: University of California, San Francisco
N=37 --> 51 | Trial primary completion date: Aug 2017 --> Jan 2018 Trial primary completion date: Dec 2015 --> Dec 2016
- | Enrollment change, Trial withdrawal: StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies (clinicaltrials.gov) - Jun 12, 2017
P2, N=0, Withdrawn, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2015 --> Dec 2016 N=30 --> 0 | Not yet recruiting --> Withdrawn
- ||| Trial completion: Dual Algorithm Post Market Clinical Study (clinicaltrials.gov) - Jun 12, 2017
P=N/A, N=100, Completed, Sponsor: MP Biomedicals, LLC
N=30 --> 0 | Not yet recruiting --> Withdrawn Enrolling by invitation --> Completed
- Vonjo (pacritinib) / SOBI
Enrollment change, Trial termination, Trial primary completion date: Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Jun 9, 2017
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Enrolling by invitation --> Completed N=40 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Jun 2017; FDA Clinical Hold
- | riluzole / Generic mfg.
Enrollment closed: Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-Protect) (clinicaltrials.gov) - Jun 8, 2017
P3, N=270, Active, not recruiting, Sponsor: AOSpine North America Research Network
N=40 --> 3 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2018 --> Jun 2017; FDA Clinical Hold Recruiting --> Active, not recruiting
- | azacitidine / Generic mfg., idarubicin hydrochloride / Generic mfg.
Trial completion, Trial primary completion date: Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes (clinicaltrials.gov) - Jun 8, 2017
P1/2, N=41, Completed, Sponsor: Groupe Francophone des Myelodysplasies
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2011
- | Trial primary completion date, IO biomarker: Predictive Clinical and Biological Parameters in Acute Leukemia, Myelodysplastic Syndromes and Myeloproliferative Disorders-HEMATO-BIO-IPC-2013-015 (clinicaltrials.gov) - Jun 8, 2017
P=N/A, N=300, Recruiting, Sponsor: Institut Paoli-Calmettes
Active, not recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2011 Trial primary completion date: May 2017 --> May 2018
- | Amevive (alefacept) / Astellas
Trial termination: Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=3, Terminated, Sponsor: Emory University
Trial primary completion date: May 2017 --> May 2018 Suspended --> Terminated; drug company is no longer making the drug
- | Enrollment change, Trial initiation date, Trial primary completion date, Adherence: TAKE-IT: Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (clinicaltrials.gov) - Jun 7, 2017
P=N/A, N=58, Completed, Sponsor: pia raanani
Suspended --> Terminated; drug company is no longer making the drug N=88 --> 58 | Initiation date: Apr 2013 --> Oct 2013 | Trial primary completion date: Apr 2014 --> Jun 2015
- Jakafi (ruxolitinib) / Incyte, Tasigna (nilotinib) / Novartis, Inhibikase
Enrollment closed, Enrollment change: Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL Patients (clinicaltrials.gov) - Jun 7, 2017
P1/2, N=5, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=88 --> 58 | Initiation date: Apr 2013 --> Oct 2013 | Trial primary completion date: Apr 2014 --> Jun 2015 Recruiting --> Active, not recruiting | N=80 --> 5
- Ninlaro (ixazomib) / Takeda
Trial termination, Trial primary completion date: Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission (clinicaltrials.gov) - Jun 5, 2017
P2, N=5, Terminated, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Active, not recruiting | N=80 --> 5 Active, not recruiting --> Terminated | Trial primary completion date: Mar 2021 --> May 2017; Slow Accrual
- ||| Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Trial completion, Metastases: Safety Study of AP24534 to Treat Chronic Myelogenous Leukemia (CML) and Other Hematological Malignancies (clinicaltrials.gov) - Jun 4, 2017
P1, N=81, Completed, Sponsor: Ariad Pharmaceuticals
Active, not recruiting --> Terminated | Trial primary completion date: Mar 2021 --> May 2017; Slow Accrual Active, not recruiting --> Completed
- | melphalan / Generic mfg., fludarabine IV / Generic mfg., thiotepa / Generic mfg.
Trial primary completion date: Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor (clinicaltrials.gov) - Jun 2, 2017
P=N/A, N=3, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: May 2017 --> May 2018
- | Onureg (azacitidine oral) / BMS
Trial completion: Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS). (clinicaltrials.gov) - Jun 2, 2017
P1/2, N=30, Completed, Sponsor: Celgene
Trial primary completion date: May 2017 --> May 2018 Active, not recruiting --> Completed
- Iclusig (ponatinib) / Takeda, Otsuka, Incyte
Enrollment change, Trial withdrawal: Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) (clinicaltrials.gov) - Jun 2, 2017
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Active, not recruiting --> Completed N=132 --> 0 | Not yet recruiting --> Withdrawn
- clofarabine / Generic mfg.
Trial termination: Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (clinicaltrials.gov) - Jun 1, 2017
P1/2, N=11, Terminated, Sponsor: University of Utah
N=132 --> 0 | Not yet recruiting --> Withdrawn Completed --> Terminated; Data analysis revealed sufficient data for safety and efficacy
- | Zolinza (vorinostat) / Merck (MSD), Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Enrollment change, Combination therapy: Vorinostat and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (clinicaltrials.gov) - Jun 1, 2017
P2, N=31, Terminated, Sponsor: Fred Hutchinson Cancer Research Center
Completed --> Terminated; Data analysis revealed sufficient data for safety and efficacy N=107 --> 31
- | Tasigna (nilotinib) / Novartis, Inhibikase
Trial primary completion date: Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - May 31, 2017
P2, N=40, Active, not recruiting, Sponsor: Cancer Trials Ireland
N=107 --> 31 Trial primary completion date: Dec 2016 --> Feb 2016
- | Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Clinical: Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA (clinicaltrials.gov) - May 31, 2017
P2/3, N=36, Completed, Sponsor: Masonic Cancer Center, University of Minnesota
Trial primary completion date: Dec 2016 --> Feb 2016 Active, not recruiting --> Completed